JP4468810B2
(ja)
|
2002-07-24 |
2010-05-26 |
キューエルティー インコーポレーティッド |
ピラゾリルベンゾチアゾール誘導体および治療薬としてのそれらの使用法
|
EP1606266A4
(de)
*
|
2003-03-21 |
2008-06-25 |
Smithkline Beecham Corp |
Chemische verbindungen
|
AR045134A1
(es)
*
|
2003-07-29 |
2005-10-19 |
Smithkline Beecham Plc |
Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic
|
JP4692281B2
(ja)
*
|
2003-08-05 |
2011-06-01 |
味の素株式会社 |
新規アゾール化合物
|
US20070004771A1
(en)
*
|
2003-10-06 |
2007-01-04 |
Glaxo Group Limited |
Preparation of 1,6,7-trisubstituted azabenzimidazoles as kinase inhibitors
|
US7547779B2
(en)
|
2003-10-06 |
2009-06-16 |
Glaxo Group Limited |
Preparation of 1,6-disubstituted azabenzimidazoles as kinase inhibitors
|
WO2005037198A2
(en)
*
|
2003-10-06 |
2005-04-28 |
Glaxo Group Limited |
Preparation of 1,7-disubstituted azabenzimidazoles as kinase inhibitors
|
TW200538453A
(en)
*
|
2004-04-26 |
2005-12-01 |
Bristol Myers Squibb Co |
Bicyclic heterocycles as kinase inhibitors
|
US7709518B2
(en)
|
2004-09-21 |
2010-05-04 |
Synta Pharmaceuticals Corp. |
Compounds for inflammation and immune-related uses
|
ATE512146T1
(de)
*
|
2004-10-13 |
2011-06-15 |
Merck Patent Gmbh |
Phenylharnstoffderivate als hemmstoffe von tyrosinkinasen zur behandlung von tumorerkrankungen
|
WO2006058120A1
(en)
*
|
2004-11-22 |
2006-06-01 |
Vertex Pharmaceuticals Incorporated |
Bicyclic inhibitors or rho kinase
|
MX2007008843A
(es)
*
|
2005-01-21 |
2007-08-22 |
Schering Corp |
Derivados de imidazol y bencimidazol utiles como antagonistas de histamina h3.
|
CR9465A
(es)
*
|
2005-03-25 |
2008-06-19 |
Surface Logix Inc |
Compuestos mejorados farmacocineticamente
|
TW200716110A
(en)
*
|
2005-04-20 |
2007-05-01 |
Smithkline Beecham Corp |
Inhibitors of AKT activity
|
GB0512844D0
(en)
*
|
2005-06-23 |
2005-08-03 |
Novartis Ag |
Organic compounds
|
US20090215857A1
(en)
*
|
2005-09-13 |
2009-08-27 |
Pfizer Products Inc. |
Therapeutic Pyrrolidines
|
US7625890B2
(en)
|
2005-11-10 |
2009-12-01 |
Smithkline Beecham Corp. |
Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors
|
US8022075B2
(en)
|
2005-11-30 |
2011-09-20 |
Fujifilm Ri Pharma Co., Ltd. |
Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition
|
RU2008130111A
(ru)
*
|
2005-12-22 |
2010-01-27 |
Алькон Рисерч, Лтд. (Us) |
(индазол-5-ил)пиразины и (1,3-дигидроиндол-2-он)пиразины для лечения опосредованнызх rно-киназой заболеваний и состояний
|
US8227603B2
(en)
*
|
2006-08-01 |
2012-07-24 |
Cytokinetics, Inc. |
Modulating skeletal muscle
|
US8299248B2
(en)
*
|
2006-08-02 |
2012-10-30 |
Cytokinetics, Incorporated |
Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
|
RS54542B1
(en)
*
|
2006-08-02 |
2016-06-30 |
Cytokinetics, Inc. |
CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS INCLUDING IMIDAZOPYRIMIDINE
|
FR2910473B1
(fr)
|
2006-12-26 |
2009-02-13 |
Sanofi Aventis Sa |
Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique.
|
UY30892A1
(es)
*
|
2007-02-07 |
2008-09-02 |
Smithkline Beckman Corp |
Inhibidores de la actividad akt
|
WO2008121333A1
(en)
*
|
2007-03-30 |
2008-10-09 |
Cytokinetics, Incorporated |
Certain chemical entities, compositions and methods
|
CN101910158A
(zh)
|
2007-10-25 |
2010-12-08 |
阿斯利康(瑞典)有限公司 |
可用于治疗细胞增殖性病症的吡啶衍生物和吡嗪衍生物
|
KR20100119773A
(ko)
*
|
2008-02-04 |
2010-11-10 |
싸이토키네틱스, 인코포레이티드 |
소정의 화학물질, 조성물 및 방법
|
CA2723852A1
(en)
*
|
2008-05-16 |
2009-11-19 |
Cellzome Ag |
Methods for the identification of parp interacting molecules and for the purification of parp proteins
|
EP2370424A1
(de)
|
2008-11-10 |
2011-10-05 |
Vertex Pharmaceuticals Incorporated |
Als inhibitoren von atr-kinase geeignete verbindungen
|
DK3354650T3
(da)
|
2008-12-19 |
2022-05-30 |
Vertex Pharma |
Forbindelser der er nyttige som inhibitorer af ATR-kinase
|
WO2010083145A1
(en)
*
|
2009-01-16 |
2010-07-22 |
Merck Sharp & Dohme Corp. |
IMIDAZO[1,2-a]PYRIDINES AND IMIDAZO[1,2-b]PYRIDAZINES AS MARK INHIBITORS
|
AU2010208265B2
(en)
*
|
2009-01-30 |
2012-12-06 |
Novartis Ag |
Crystalline N-{(1 S)-2-amino-1-[(3- fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1 H-pyrazol-5-yl)-2- thiophenecarboxamide hydrochloride
|
JP6189581B2
(ja)
|
2009-02-20 |
2017-08-30 |
セルラー ダイナミクス インターナショナル, インコーポレイテッド |
幹細胞の分化のための方法および組成物
|
WO2010099539A1
(en)
|
2009-02-27 |
2010-09-02 |
Cellular Dynamics International, Inc. |
Differentiation of pluripotent cells
|
WO2011034741A1
(en)
*
|
2009-09-15 |
2011-03-24 |
Merck Sharp & Dohme Corp. |
Imidazopyridin-2-one derivatives
|
SG181947A1
(en)
*
|
2009-12-30 |
2012-07-30 |
Arqule Inc |
Substituted imidazopyridinyl-aminopyridine compounds
|
WO2011143425A2
(en)
|
2010-05-12 |
2011-11-17 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
EP2569289A1
(de)
|
2010-05-12 |
2013-03-20 |
Vertex Pharmaceuticals Incorporated |
Pyrazine als hemmer der atr-kinase
|
JP2013529200A
(ja)
|
2010-05-12 |
2013-07-18 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Atrキナーゼ阻害剤として有用な化合物
|
AU2011253021A1
(en)
|
2010-05-12 |
2012-11-29 |
Vertex Pharmaceuticals Incorporated |
2 -aminopyridine derivatives useful as inhibitors of ATR kinase
|
JP2013526538A
(ja)
|
2010-05-12 |
2013-06-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Atrキナーゼ阻害剤として有用な化合物
|
AU2011253025A1
(en)
|
2010-05-12 |
2012-11-29 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
MX2013000103A
(es)
|
2010-06-23 |
2013-06-13 |
Vertex Pharma |
Derivados de pirrolo-pirazina utiles como inhibidores de cinasa art.
|
DK2638149T3
(da)
|
2010-11-12 |
2019-08-12 |
Univ Georgetown |
Immortalisering af epitelceller og fremgangsmåder til anvendelse
|
KR20140027974A
(ko)
|
2011-04-05 |
2014-03-07 |
버텍스 파마슈티칼스 인코포레이티드 |
Tra 키나제의 억제제로서 유용한 아미노피라진 화합물
|
JP2014522818A
(ja)
|
2011-06-22 |
2014-09-08 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Atrキナーゼ阻害剤として有用な化合物
|
EP2723745A1
(de)
|
2011-06-22 |
2014-04-30 |
Vertex Pharmaceuticals Inc. |
Als art-kinasehemmer nützliche verbindungen
|
JP2014517079A
(ja)
|
2011-06-22 |
2014-07-17 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Atrキナーゼ阻害剤として有用な化合物
|
WO2012177852A1
(en)
|
2011-06-24 |
2012-12-27 |
Arqule, Inc |
Substituted imidazopyridinyl compounds
|
BR112013033182A2
(pt)
|
2011-06-24 |
2016-09-06 |
Arqule Inc |
compostos imidazopiridinil-aminopiridina substituída
|
CN102295594B
(zh)
*
|
2011-07-12 |
2016-01-20 |
上海医药工业研究院 |
4-n-取代-1-(3-甲氧基丙基)-4-哌啶胺类化合物及制备和应用
|
EP2731611B1
(de)
|
2011-07-13 |
2019-09-18 |
Cytokinetics, Inc. |
Kombinationstherapie gegen als
|
EP2751088B1
(de)
|
2011-09-30 |
2016-04-13 |
Vertex Pharmaceuticals Incorporated |
Als atr-kinasehemmer nützliche verbindungen
|
JP6162126B2
(ja)
|
2011-09-30 |
2017-08-23 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
Atr阻害剤による膵臓癌及び非小細胞肺癌の治療
|
SG11201401093WA
(en)
|
2011-09-30 |
2014-04-28 |
Vertex Pharma |
Processes for making compounds useful as inhibitors of atr kinase
|
US8846686B2
(en)
|
2011-09-30 |
2014-09-30 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
WO2013049720A1
(en)
|
2011-09-30 |
2013-04-04 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
EP2776420A1
(de)
|
2011-11-09 |
2014-09-17 |
Vertex Pharmaceuticals Incorporated |
Pyrazinverbindungen als atr-kinaseinhibitoren
|
US8846917B2
(en)
|
2011-11-09 |
2014-09-30 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
JP2015502925A
(ja)
|
2011-11-09 |
2015-01-29 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
Atrキナーゼの阻害剤として有用なピラジン化合物
|
US8841337B2
(en)
|
2011-11-09 |
2014-09-23 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
US8846918B2
(en)
|
2011-11-09 |
2014-09-30 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
HUE035253T2
(en)
|
2012-04-05 |
2018-05-02 |
Vertex Pharma |
Compounds and combination therapies useful as inhibitors of ATR kinase
|
US9260696B2
(en)
|
2012-04-24 |
2016-02-16 |
Dan S. Kaufman |
Method for developing natural killer cells from stem cells
|
US9226922B2
(en)
|
2012-09-28 |
2016-01-05 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
JP6280554B2
(ja)
*
|
2012-09-28 |
2018-02-14 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
Erk阻害剤である新規化合物
|
EP2904406B1
(de)
|
2012-10-04 |
2018-03-21 |
Vertex Pharmaceuticals Incorporated |
Verfahren zur bestimmung der durch atr-inhibition auftretenden vermehrten dna-schädigung
|
EP2909202A1
(de)
|
2012-10-16 |
2015-08-26 |
Vertex Pharmaceuticals Incorporated |
Als atr-kinaseinhibitoren nützliche verbindungen
|
HUE052808T2
(hu)
|
2012-12-07 |
2021-05-28 |
Vertex Pharma |
Pirazolo[1,5-A]pirimidinek alkalmazása ATR kináz inhibítorként, rákos megbetegedések kezelésére
|
GB201304526D0
(en)
*
|
2013-03-13 |
2013-04-24 |
Proximagen Ltd |
New compounds
|
AU2014236150B2
(en)
|
2013-03-14 |
2019-10-31 |
The Regents Of The University Of California |
In vitro production of medial ganglionic eminence precursor cells
|
TR201911151T4
(tr)
|
2013-03-14 |
2019-08-21 |
Tolero Pharmaceuticals Inc |
Jak2 ve alk2 inhibitörleri ve bunların kullanım yöntemleri.
|
EP2970286A1
(de)
|
2013-03-15 |
2016-01-20 |
Vertex Pharmaceuticals Inc. |
Kondensierte pyrazolopyrimidinderivate als inhibitoren der atr-kinase
|
EA028512B1
(ru)
|
2013-05-14 |
2017-11-30 |
Эктив Байотек Аб |
N-(гетероарил)сульфонамидные производные, которые могут применяться в качестве s100-ингибиторов
|
WO2015041533A1
(en)
|
2013-09-20 |
2015-03-26 |
Stichting Het Nederlands Kanker Instituut |
Rock in combination with mapk-pathway
|
RS59679B1
(sr)
|
2013-12-06 |
2020-01-31 |
Vertex Pharma |
Jedinjenje 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-karboksamida korisno kao inhibitor atr kinaze, njegovo dobijanje, različiti čvrsti oblici i njegovi radioaktivno obeleženi derivati
|
BR112016024521A2
(pt)
*
|
2014-04-22 |
2017-08-15 |
Arqule Inc |
sais e polimorfos de um composto imidazopiridinil-aminopiridina
|
SI3152212T1
(sl)
|
2014-06-05 |
2020-06-30 |
Vertex Pharmaceuticals Inc. |
Radioaktivno označeni derivati 2-amino-6-fluoro-N-(5-fluoro-piridin-3-IL)-pirazolo (1,5-A)pirimidin-3- karboksamidne spojine, koristni kot inhibitor kinaze ATR, priprava navedene spojine in njene različne trdne oblike
|
RS59054B1
(sr)
|
2014-06-17 |
2019-08-30 |
Vertex Pharma |
Postupak za lečenje raka korišćenjem kombinacije chk1 i atr inhibitora
|
KR20170020527A
(ko)
|
2014-06-27 |
2017-02-22 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
배양된 포유동물 윤부 줄기세포, 이를 생성하는 방법, 및 이의 용도
|
AU2015353853B2
(en)
|
2014-11-25 |
2020-10-15 |
President And Fellows Of Harvard College |
Methods for generation of podocytes from pluripotent stem cells and cells produced by the same
|
US10100285B2
(en)
|
2015-04-03 |
2018-10-16 |
Propagenix Inc. |
Ex vivo proliferation of epithelial cells
|
SG10201902872YA
(en)
|
2015-04-03 |
2019-04-29 |
Propagenix Inc |
Ex vivo proliferation of epithelial cells
|
DK3347450T3
(da)
|
2015-09-11 |
2021-05-31 |
Propagenix Inc |
Ex vivo-proliferation af epithelceller
|
WO2017059357A1
(en)
|
2015-09-30 |
2017-04-06 |
Vertex Pharmaceuticals Incorporated |
Method for treating cancer using a combination of dna damaging agents and atr inhibitors
|
WO2017066705A1
(en)
*
|
2015-10-14 |
2017-04-20 |
Aquinnah Pharmaceuticals, Inc. |
Compounds, compositions and methods of use against stress granules
|
US20190060286A1
(en)
|
2016-02-29 |
2019-02-28 |
University Of Florida Research Foundation, Incorpo |
Chemotherapeutic Methods
|
WO2019126567A1
(en)
*
|
2017-12-22 |
2019-06-27 |
Southern Research Institute |
Substituted heterocyclic-pyridinones as hiv-1 nef-hck inhibitors
|
CA3103995A1
(en)
|
2018-07-26 |
2020-01-30 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
|
EP3841195A1
(de)
|
2018-08-20 |
2021-06-30 |
Propagenix Inc. |
Epithelzellsphäroide
|
US20210292766A1
(en)
|
2018-08-29 |
2021-09-23 |
University Of Massachusetts |
Inhibition of Protein Kinases to Treat Friedreich Ataxia
|
SI3860998T1
(sl)
|
2018-10-05 |
2024-06-28 |
Annapurna Bio Inc. |
Spojine in sestavki za zdravljenje stanj, povezanih z aktivnostjo apj-receptorja
|
UY38427A
(es)
|
2018-10-26 |
2020-05-29 |
Novartis Ag |
Métodos y composiciones para terapia con células oculares
|
CN111732584B
(zh)
*
|
2019-03-25 |
2024-02-27 |
复旦大学 |
二芳基取代稠杂环类化合物及其制备方法和在制药中的用途
|
WO2021220132A1
(en)
|
2020-04-27 |
2021-11-04 |
Novartis Ag |
Methods and compositions for ocular cell therapy
|
KR20240099268A
(ko)
|
2021-10-18 |
2024-06-28 |
에비아 라이프 사이언시스 인코포레이션 |
간 섬유증 치료를 한 조성 및 사용 방법
|
AU2022369459A1
(en)
|
2021-10-22 |
2024-05-30 |
Evia Life Sciences Inc. |
Methods for making extracellular vesicles, and compositions and methods of use thereof
|
WO2024083237A1
(en)
*
|
2022-10-20 |
2024-04-25 |
Impact Therapeutics (Shanghai) , Inc |
Substituted heteroaryl bicyclic compounds as usp1 inhibitors and the use thereof
|